Manara - Qatar Research Repository
Browse

Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study

Download (588.68 kB)
journal contribution
submitted on 2024-04-04, 09:24 and posted on 2024-05-05, 09:26 authored by Farah M. Shurrab, Duaa W. Al-Sadeq, Haissam Abou-Saleh, Nader Al-Dewik, Amira E. Elsharafi, Fatima M. Hamaydeh, Bushra Y. Abo Halawa, Tala M. Jamaleddin, Huda M. Abdul Hameed, Parveen B. Nizamuddin, Fathima Humaira Amanullah, Hanin I. Daas, Laith J. Abu-Raddad, Gheyath K. Nasrallah

The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (<30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.

Other Information

Published in: Vaccines
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.3390/vaccines10020191


Additional institutions affiliated with: Hamad Medical Corporation, Interim Translational Research Institute - HMC, Hamad General Hospital - HMC, Women's Wellness and Research Center - HMC

Funding

Seroprevalence SARS-COV2 antibodies among naturally infected and vaccinated individualsin the Qatar University community - https://app.dimensions.ai/details/grant/grant.9764879

History

Language

  • English

Publisher

MDPI

Publication Year

  • 2022

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Bin Khalifa University
  • College of Health and Life Sciences - HBKU
  • Qatar University
  • Biomedical Research Center - QU
  • College of Arts and Sciences - QU
  • Qatar University Health - QU
  • College of Medicine - QU HEALTH
  • College of Dental Medicine - QU HEALTH
  • Weill Cornell Medicine - Qatar

Usage metrics

    College of Health and Life Sciences - HBKU

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC